Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BCLI Brainstorm Cell Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: BCLI
Price (delayed)
$1.31
Market cap
$10.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.07
Enterprise value
$10.53M
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of
Highlights
The EPS has surged by 57% year-on-year and by 10% since the previous quarter
BCLI's quick ratio is up by 33% YoY
The equity has contracted by 34% YoY but it has grown by 4% from the previous quarter
BCLI's debt has soared by 74% from the previous quarter and by 58% YoY
Key stats
What are the main financial stats of BCLI
Market
Valuations
Earnings
Shares outstanding
7.94M
Market cap
$10.4M
Enterprise value
$10.53M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$12.31M
Net income
-$11.09M
EBIT
-$10.97M
EBITDA
-$10.74M
Free cash flow
-$7.66M
Per share
Balance sheet
Liquidity
EPS
-$2.07
EPS diluted
-$2.07
Free cash flow per share
-$1.21
Book value per share
-$1.14
Revenue per share
$0
TBVPS
$0.56
Total assets
$3.57M
Total liabilities
$11.03M
Debt
$1.77M
Equity
-$7.46M
Working capital
-$8.57M
Debt to equity
-0.24
Current ratio
0.21
Quick ratio
0.16
Net debt/EBITDA
-0.01
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-338.2%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCLI stock price
How has the Brainstorm Cell Therapeutics stock price performed over time
Intraday
14.91%
1 week
18.02%
1 month
7.38%
1 year
-75.56%
YTD
-42.29%
QTD
16.96%
Financial performance
How have Brainstorm Cell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.31M
Net income
-$11.09M
Gross margin
N/A
Net margin
N/A
Brainstorm Cell Therapeutics's operating income has increased by 34% YoY but it has decreased by 5% QoQ
The net income has increased by 29% YoY and by 4.6% QoQ
Price vs fundamentals
How does BCLI's price correlate with its fundamentals
Growth
What is Brainstorm Cell Therapeutics's growth rate over time
Valuation
What is Brainstorm Cell Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 57% year-on-year and by 10% since the previous quarter
The equity has contracted by 34% YoY but it has grown by 4% from the previous quarter
Efficiency
How efficient is Brainstorm Cell Therapeutics business performance
The return on assets has increased by 6% since the previous quarter but it has declined by 3.3% year-on-year
Dividends
What is BCLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCLI.
Financial health
How did Brainstorm Cell Therapeutics financials performed over time
Brainstorm Cell Therapeutics's total assets is 68% less than its total liabilities
Brainstorm Cell Therapeutics's total assets has soared by 95% from the previous quarter and by 7% YoY
BCLI's quick ratio is up by 33% YoY
BCLI's debt is 124% more than its equity
The company's debt to equity has shrunk by 85% QoQ and by 20% YoY
BCLI's debt has soared by 74% from the previous quarter and by 58% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.